When was Prokarium founded?

Prokarium was founded in 2012 and raised its 1st funding round 3 years after it was founded.

Where is Prokarium located?

Prokarium is headquartered in London, United Kingdom. It is registered at London Bioscience Innovation Centre, 2 Royal College Street, London, NW1 0NH.

Which legal entities is Prokarium associated with?

Prokarium is associated with PROKARIUM HOLDINGS LTD and 1 other.

How many employees does Prokarium have?

As of Dec 31, 2025, the latest employee count at Prokarium is 24.

Is Prokarium a funded company?

Prokarium is a funded company, having raised a total of $70M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 03, 2015.

How much is Prokarium worth?

The latest valuation of Prokarium is £***** as of Jan 10, 2023.

When was the latest funding round of Prokarium?

Prokarium's latest funding was a $***** Series C round on Jan 10, 2023, with participation from 1 investor. Its primary sector is Infectious Diseases. In United Kingdom, the Infectious Diseases sector has seen $139M in funding in 2026 to date.

Where does Prokarium rank among its competitors?

Prokarium ranks 19th amongst 199 active competitors, of which 47 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Prokarium?

Prokarium's top competitors include Vaxart, Insmed and UroGen Pharma. Among them, Basilea secured the most recent funding round in May, 2026.

Prokarium - 2026 Company Profile, Team, Funding, Competitors & Financials

Prokarium is a series C company based in London (United Kingdom), founded in 2012. It operates as a Developer of bacterial immunotherapy treatments for various types of cancer. Prokarium has raised $70M in funding from Riyadh Valley Company and Korea Investment Holdings, with a current valuation of £*****. The company has 199 active competitors, including 47 funded and 50 that have exited. Its top competitors include companies like Vaxart, Insmed and UroGen Pharma.

Company Details

Developer of bacterial immunotherapy treatments for various types of cancer. The company leverages synthetic biology to reprogram bacteria specifically using its proprietary ZH9 strain to function as a therapeutic delivery platform for oncology and other medical applications.

Website: www.prokarium.com/
Phone Number: +55 **********
Registered Address: London Bioscience Innovation Centre, 2 Royal College Street, London, NW1 0NH

Key Metrics

Founded Year

2012

Location

London, United Kingdom

Stage

Series C

Total Funding

$70M in 6 rounds

Latest Funding Round

Series C, Jan 10, 2023, $*****

Post Money Valuation

£***** as on Jan 10, 2023

Investors

Riyadh Valley Company & 10 more

Ranked

19^th among 199 active competitors

Employee Count

24 as on Dec 31, 2025

Similar Companies

Vaxart & 260 more

View Prokarium's full profile

Prokarium is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PROKARIUM HOLDINGS LTD CIN: 8933971 , United Kingdom, Active		-	12 (As on Dec 31, 2025)
Prokarium Limited CIN: 6300883 , Germany, Active	Jul 02, 2017	-	12 (As on Dec 31, 2025)

Prokarium has raised a total funding of $70M over 6 rounds. Its first funding round was on Aug 03, 2015. Its latest funding round was a Series C round on Jan 10, 2023 for $*****. 1 investor participated in its latest round. Prokarium has 9 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Prokarium:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 10, 2023	2640692	Series C	2768851	7467772	9912414	6261938
Oct 26, 2020	9114262	Series B	6117744	4964013	5345854	Riyadh Valley Company
Oct 08, 2019	4072333	Grant (prize money)	7419972	5656340	9801425	Wellcome Trust

Access funding benchmarks and valuations. Sign up today!

View details of Prokarium's funding rounds and investors

Here are the details of Prokarium's key team members:

Ibraheem Mahmood: CEO of Prokarium. They serve on the board of 1 company.

Prokarium's Board of Directors

Prokarium's board has 3 active members. Ted Fjallman is part of team and Kristen Albright and Thomas Bengt Eldered are independent board members.

Here is the list of Prokarium's board of directors:

Name	Type	Representing	Status	Duration
ltapnwr	Team	-	Current	6y 3m
Kristen Albright	Independent board member	-	Current	0y 8m
yfnkfyi	Independent board member	-	Current	4y 9m

View details of Prokarium's Founder profiles and Board Members

Prokarium's employee count trend

Prokarium has 24 employees as of Dec 25. The total employee count is 25.0% lower than what it was in Dec 24. Here is Prokarium's employee count trend over the years:

Uncover Prokarium's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Prokarium include Vaxart, Insmed and UroGen Pharma. Here is the list of Top 10 competitors of Prokarium, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
2nd	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
3rd	UroGen Pharma 2004, Ra anana (Israel), Public	Developer of therapeutics to treat urothelial and specialty cancers	$7M	Sonostar Ventures, hortoncapital.com & 12 others	64/100
4th	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	61/100
5th	SNIPR Biome 2011, Copenhagen (Denmark), Series B	Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely	$139M	Lundbeck Foundation, Life Sciences Partners ... & 7 others	61/100
6th	SpyBiotech 2017, Oxford (United Kingdom), Series A	Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology	$39M	Braavos, Oxford Science Enterprises & 6 others	61/100
7th	Affinivax 2013, Cambridge (United States), Acquired	Developer of technology-based conjugate vaccines against infectious diseases	$359M	Gates, Foresite Capital & 14 others	59/100
8th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
9th	TuHURA Biosciences 1996, Tampa (United States), Public	Developer of immunotherapies for the treatment of cancer	$41.5M	HHS, Valirx & 1 others	58/100
10th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	REPAIR Impact Fund, Boehringer Ingelheim Venture Fund ... & 32 others	58/100
19th	Prokarium 2012, London (United Kingdom), Series C	Developer of bacterial immunotherapy treatments for various types of cancer	$70M	British Business Bank, Riyadh Valley Company ... & 9 others	52/100